Clinical Trials Browser

Recruiting × Thrombocythemia, Essential × 30 days × Clear all

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06661915 2026-03-18

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT04282187 2026-03-16

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

Phase 2 Recruiting

25 enrolled

MyeloidOther hematologic neoplasm

Leukemia, Monocytic, Acute, Myelodysplastic Syndromes, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

NCT06034002 2026-03-16

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

230 enrolled

Myeloid

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT07008118 2026-03-16

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Phase 1 Recruiting

120 enrolled

Myeloid

Myeloproliferative Disorders, Thrombocythemia, Essential, Primary Myelofibrosis

NCT05123365 2026-03-10

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

Phase 1/2 Recruiting

27 enrolled

Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT06351631 2026-02-20

MK-3543-017

Phase 3 Recruiting

400 enrolled

Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Clinical Trials

Study of INCA036978 in Participants With Myeloproliferative Neoplasms

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

MK-3543-017